External Validation of Bioinfogate’s OFF-X FAERS Curation Process & Statistical Signal Extraction to be Supported By INTAGE Healthcare's CzeekV Pro

Bioinfogate, a leading healthcare data science organization, today announced it has established an agreement with INTAGE Healthcare to perform an external validation of the methodologies used by Bioinfogate to curate information from FAERS (FDA Adverse Event Reporting System) and extract safety signals using a variety of well-established statistical methods with the CzeekV Pro database system.


Based on its longstanding experience managing and curating information from the FAERS database, INTAGE Healthcare has provided computed reports and signals from a range of drugs and treatments. These results will be used by Bioinfogate as an external validation set and as an additional quality control layer in its translational safety intelligence portal, OFF-X.

INTAGE Healthcare is the producer of the CzeekV Pro database system, offered since 2010, a curated database of FAERS and JADER spontaneous adverse reports and signals based on well-established methods used by a variety of regulatory bodies worldwide.

OFF-X is widely used by pharmacovigilance professionals in major pharmaceutical companies and biotech organizations. By fully integrating FAERS and JADER curated reports and signals into its existing pharmacovigilance functionalities and translational approach, OFF-X will offer a unique integrated view of factual safety intelligence.

About OFF-X®

Launched in 2016, OFF-X® is used across pharma and biotech organizations, in leading research centers and by regulatory bodies around the world, addressing the need for new approaches to enhance safety assessments that can reduce patient burden and avoid costly failures.

The Bioinfogate OFF-X® portal provides integrated target discovery, non-clinical and clinical adverse event intelligence and pharmacovigilance insights for drugs and targets in all phases of drug R&D and post-marketing.

By delivering critical integrated target discovery, preclinical toxicity, clinical adverse event intelligence and pharmacovigilance insights coupled to advanced analytics, Bioinfogate OFF-X, allows safety liabilities to be monitored and anticipated across all phases of drug R&D and post-marketing. OFF-X is updated daily and more than 4,000 expertly curated alerts are added to the portal each week.

As of March 2021, the portal covers a range of over 15,000 targets and 21,500 drugs & biologics, and is populated with more than 1.1 million expertly curated safety alerts associated to over 10,000 adverse effects. OFF-X® is used across pharma and biotech organizations, in leading research centers and regulatory bodies.

For more information visit targetsafety.info.

About INTAGE Healthcare

INTAGE Healthcare is a leading healthcare marketing intelligence and evidence provider headquartered in Japan. INTAGE Healthcare provides comprehensive pre-launch and post-launch support to meet the full range of healthcare information needs through real-world data analytics, post-marketing surveillance, and marketing research. They combine their deep knowledge of clinical practice with the INTAGE Group’s abundant resources and strength in consumer insights to provide healthcare consumers, providers, manufacturers, and service companies with the information they need to make healthier decisions.

For more information visit intage-healthcare.co.jp.

About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.


Investor Relations Contact
Mark Donohue, Head of Investor Relations
+1 (215) 243 2202


Media Contact
Tabita Seagrave, Head of Global Corporate Communications

Subscribe to our news

Let's stay in touch. Subscribe to our latest announcements.